Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4Active not recruiting 3Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Melanoma 11Leukemia, Myeloid, Acute 5Uveal Melanoma 4Prostatic Neoplasms 4Myelodysplastic Syndromes 4Uterine Cervical Neoplasms 3Sarcoma 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Gastrointestinal Stromal Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Gliosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Docetaxel 158Prednisone 131Leuprolide 95bicalutamide 86enzalutamide 83Radiotherapy 80Goserelin 80Abiraterone Acetate 76acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54Magnetic Resonance Spectroscopy 46Zoledronic Acid 44gallium 68 PSMA-11 37Flutamide 34abiraterone 32Estramustine 32radium Ra 223 dichloride 30apalutamide 27Surveys and Questionnaires 26Gonadotropin-Releasing Hormone 26Androgen Antagonists 25cabazitaxel 24Radiosurgery 24Dutasteride 22sipuleucel-T 21Prednisolone 21Triptorelin Pamoate 20Paclitaxel 20luprolide acetate gel depot 19Radiation 19Exercise 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms × CTLA-4 Antigen × Clear all
NCT02601014 2022-02-03

STARVE-PC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
32 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT01498978 2020-10-14

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Completed
10 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT00064129 2020-07-30

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
Genitourinary

Prostatic Neoplasms

NCT00170157 2017-05-15

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

Mayo Clinic

Phase 2 Completed
112 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡